Sanofi SA
SNW
Company Profile
Business description
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Contact
46, Avenue de la Great Army
Paris75017
FRAT: +33 153774000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
82,878
Stocks News & Analysis
stocks
Most popular shares in SMSFs
With data showing the continued rise of SMSFs, we explore the top stock picks of individual investors
stocks
Will China strong arm BHP into lower iron ore prices?
Allegations that the Chinese government told steel mills to stop buying from BHP shake markets.
stocks
Chart of the Week: Where Morningstar sees attractive dividend yields in 26/27
Charts from the Australian Dividend Outlook show the sectors where they are abundant.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,264.30 | 8.50 | 0.09% |
| CAC 40 | 7,918.00 | 123.36 | -1.53% |
| DAX 40 | 24,241.46 | 369.79 | -1.50% |
| Dow JONES (US) | 45,479.60 | 878.82 | -1.90% |
| FTSE 100 | 9,427.47 | 81.93 | -0.86% |
| HKSE | 26,290.32 | 462.27 | -1.73% |
| NASDAQ | 22,204.43 | 820.20 | -3.56% |
| Nikkei 225 | 48,088.80 | 491.64 | -1.01% |
| NZX 50 Index | 13,467.26 | 103.60 | -0.76% |
| S&P 500 | 6,552.51 | 182.60 | -2.71% |
| S&P/ASX 200 | 8,958.30 | 9.20 | 0.10% |
| SSE Composite Index | 3,897.03 | 36.94 | -0.94% |